Combination of Ivonescimab and Chemotherapy Enhances Survival Rates in EGFR+ NSCLC Patients

Recent research has shown that the addition of ivonescimab, a novel bispecific antibody designed to target both PD-1 and VEGF, significantly enhances progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC) who possess EGFR mutations and have experienced disease progression after treatment with third-generation EGFR tyrosine kinase inhibitors (TKIs).

The findings were presented at the 2025 World Conference on Lung Cancer (WCLC) by a team from UCLA Health, led by a prominent researcher in the field. The study, known as the global Phase III HARMONi trial, involved a randomized, double-blind, placebo-controlled design and included 438 participants from various regions worldwide, with a notable representation (38%) from North America and Europe. The median age of the enrolled patients was 62 years, and approximately 24.7% had brain metastases upon entering the study.

Participants received either ivonescimab (20 mg/kg) or a placebo in conjunction with standard chemotherapy agents pemetrexed and carboplatin for four cycles, followed by maintenance therapy. The primary analysis, which included a median follow-up of 22.3 months and focused on 345 patients, revealed that the combination of ivonescimab and chemotherapy reduced the risk of disease progression or mortality by 48% compared to the chemotherapy-only group.

The median PFS was reported at 6.8 months for those receiving ivonescimab, as opposed to 4.4 months for the control group. This PFS advantage was consistent across various predefined subgroups, including patients with brain metastases, where the hazard ratio was 0.34, indicating a significant benefit.

In the final overall survival (OS) analysis, which had a median follow-up of 29.7 months, the median OS for the ivonescimab group was 16.8 months, compared to 14.0 months for those receiving chemotherapy alone. The overall response rate was also higher in the ivonescimab group, at 44.7%, compared to 34.2% in the control arm. Additionally, improvements were noted in intracranial PFS, highlighting the treatment's effectiveness.

While the incidence of grade >=3 treatment-related adverse events was 50.0% among patients treated with ivonescimab, this was somewhat higher than the 42.2% observed in the control group. The most common adverse events included various laboratory abnormalities. Notably, VEGF-related complications, such as reversible hypertension and proteinuria, were more prevalent in the ivonescimab cohort but generally manageable. Treatment-related mortality was rare, reported at 1.8% in the ivonescimab group versus 2.3% in the control group.

Experts in the field have emphasized that the combination of ivonescimab and chemotherapy offers a clinically meaningful and statistically significant enhancement in progression-free survival, while also maintaining an acceptable safety profile for this challenging patient demographic. The benefits of this treatment strategy were apparent across diverse patient subgroups, regardless of the presence of brain metastases or geographic location.